Form of Warrant to Purchase Common Stock of ZymoGenetics, Inc.



 “[*]” = omitted, confidential material, which material has been separately filed with the
Securities and Exchange Commission pursuant to a request for confidential treatment. 
 EXHIBIT 10.6 
 EXHIBIT C 
 FORM OF DEERFIELD
WARRANT 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OR REDEMPTION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS (I) A REGISTRATION STATEMENT REGISTERING SUCH SECURITIES UNDER
THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE, (II) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OR
QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS, OR (III) SUCH SECURITIES ARE SOLD PURSUANT TO RULE 144 OR RULE 144A. 
 THE COMPANY
SHALL NOT ISSUE PURSUANT TO THIS CERTIFICATE AND ANY OTHER WARRANT CERTIFICATES OR OTHER SECURITIES OF THE COMPANY ISSUED PURSUANT TO THE FACILITY AGREEMENT DATED AS OF JUNE 26, 2008 (THE “FACILITY AGREEMENT”), AS AMENDED FROM TIME TO
TIME, AND THE HOLDER SHALL HAVE NO RIGHT TO ACQUIRE PURSUANT TO THIS CERTIFICATE AND ANY OTHER WARRANT CERTIFICATES OR OTHER SECURITIES OF THE COMPANY ISSUED PURSUANT TO THE FACILITY AGREEMENT, ANY SHARES OF COMMON STOCK UPON EXERCISE AND/OR
CONVERSION OF THIS CERTIFICATE AND ANY OTHER WARRANT CERTIFICATES OR OTHER SECURITIES OF THE COMPANY ISSUED PURSUANT TO THE FACILITY AGREEMENT, THAT WOULD IN THE AGGREGATE EXCEED 13,675,091 SHARES OF COMMON STOCK. COPIES OF THE FACILITY AGREEMENT
MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY. 
 AN INVESTMENT IN THESE
SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED. 
 Warrant to
Purchase 
  

			
	 [            ] shares
	 	Warrant Number [            ]

 Warrant to Purchase Common Stock 
 of 
 ZYMOGENETICS, INC. 
 THIS CERTIFIES that [DEERFIELD PRIVATE DESIGN INTERNATIONAL, L.P. /DEERFIELD PRIVATE DESIGN FUND, L.P.] or any subsequent holder(s) hereof (“Holder”) has the
right to purchase from ZYMOGENETICS, INC., a Washington corporation, (the “Company”),
[                                        ]
([            ]) fully paid and nonassessable shares, of the Company’s common stock, no par value per share (“Common Stock”), subject to adjustment as provided herein,
at a price equal to the Exercise Price (as defined in Section 3 below), at any time during the Term (as defined below). 
 Holder agrees with the
Company that this Warrant to Purchase Common Stock of the Company (this “Warrant” or this “Agreement”) is issued and all rights hereunder shall be held subject to all of the conditions, limitations and provisions set forth
herein. 
  

	1.	Date of Issuance and Term. 

 This Warrant shall be deemed to be
issued on                      (the “Date of Issuance”). The term of this Warrant begins on the Date of Issuance and ends at
5:00 p.m., New York City time, on                      [FOR FIRST WARRANTS, SIX YEARS FROM DATE FACILITY AGREEMENT IS EXECUTED; FOR
OTHER WARRANTS, SIX YEARS FROM DISTRIBUTION DATE] (the “Term”). This Warrant was issued in conjunction with that certain Facility Agreement (the 








 
“Facility Agreement”) and the Registration Rights Agreement (“Registration Rights Agreement”) by and among the Company, Deerfield Private
Design Fund, L.P. and Deerfield Private Design International, L.P., each dated June 26, 2008, entered into in conjunction herewith. 
 Notwithstanding
anything herein to the contrary, the Company shall not issue to the Holder, and the Holder may not acquire, a number of shares of Common Stock upon exercise of this Warrant to the extent that, upon such exercise, the number of shares of Common Stock
then beneficially owned by the Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Securities Exchange Act of
1934 (the “Exchange Act”) (including shares held by any “group” of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have
limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) would exceed 9.98% of the total number of shares of Common Stock then issued and outstanding. For purposes hereof, “group” has the
meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the Securities and Exchange Commission (the “SEC”), and the percentage held by the Holder shall be determined in a manner consistent with the
provisions of Section 13(d) of the Exchange Act. Upon the written request of the Holder, the Company shall, within two (2) Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.

 Further, notwithstanding anything to the contrary, the Company shall not issue pursuant to this Warrant and any other Warrants or other securities of the
Company issued pursuant to the Facility Agreement, and the Holder shall have no right to acquire pursuant to this Warrant and any other Warrants or other securities of the Company issued pursuant to the Facility Agreement, any shares of Common Stock
upon exercise and/or conversion of this Warrant and any other Warrants or other securities of the Company issued pursuant to the Facility Agreement, that would in the aggregate exceed 13,675,091 shares of Common Stock; and, provided further, that
the foregoing limitation shall not be construed to require any other issuance or other payment, distribution or otherwise by the Company of any additional securities, payments or otherwise. 
 “Affiliate” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”). With respect to a Holder of Warrants, any investment fund or managed account that is
managed on a discretionary basis by the same investment manager as such Holder will be deemed to be an Affiliate of such Holder. 
 “Business Day”
means a day on which banks are open for business in New York, New York, United States of America. 
 “Holder” means [Deerfield Private Design
International, L.P./Deerfield Private Design Fund, L.P.] and any transferee or assignee pursuant to the terms of this Warrant. 
  

	2.	Exercise. 

 (a) Manner of Exercise. During the Term, this
Warrant may be Exercised as to all or any lesser number of full shares of Common Stock covered hereby (the “Warrant Shares” or the “Shares”) upon surrender of this Warrant, with the Exercise Form attached hereto as
Exhibit A (the “Exercise Form”) duly completed and executed, at the office of the Company, Zymogenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102, Attn: Chief Financial Officer, Phone: (206) 442-6600, Fax:
(206) 442-6580, or at such other office or agency as the Company may designate in writing, by overnight mail, with an advance copy of the Exercise Form sent to the Company and its transfer agent (“Transfer Agent”) by facsimile (such
surrender hereinafter called the “Exercise” of this Warrant). 
 (b) Date of Exercise. The “Date of Exercise” of the Warrant shall
be defined as the date that the Exercise Form attached hereto as Exhibit A, completed and executed, and the original Warrant are received by the Company pursuant to Section 3 below. Upon receipt of the properly completed and
executed Exercise Form and the original Warrant by the Company, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been Exercised, irrespective of
the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares as the case may be. 
 (c) Delivery of Common Stock Upon Exercise. Within three (3) Business Days after any Date of Exercise (plus any additional days caused by any incorrect or incomplete information provided by Holder to the
Company hereunder (the “Delivery Period”), the Company shall issue and deliver (or cause its Transfer Agent so to issue and deliver) in accordance with the terms hereof to or upon the order of the Holder that number of shares of Common
Stock (“Exercise Shares”) for the portion of this Warrant converted as shall be determined in accordance herewith. Upon the Exercise of this Warrant or any part thereof, the Company shall, at its own cost and expense, take all reasonable
action, including, as necessary, obtaining 

  


					
		 	-2-	 	[  *  ] Confidential Treatment Requested









 
and delivering, an opinion of counsel to assure that the Transfer Agent shall issue stock certificates in the name of Holder (or its nominee) or such other
persons as designated by Holder and in such denominations to be specified at Exercise representing the number of shares of Common Stock issuable upon such Exercise. The Company warrants that no instructions contrary to these instructions have been
or will be given to the Transfer Agent and that, unless waived by the Holder, this Warrant and the Exercise Shares will be free-trading, and freely transferable, and will not contain a legend restricting the resale or transferability of the Exercise
Shares if the Unrestricted Conditions (as defined below) are met. 
 (d) Delivery Failure. In addition to any other remedies which may be available to
the Holder, in the event that the Company fails for any reason to effect delivery of the Exercise Shares by the end of the Delivery Period (a “Delivery Failure”), the Holder will be entitled to revoke all or part of the relevant Exercise
Form by delivery of a notice to such effect to the Company whereupon the Company and the Holder shall each be restored to their respective positions immediately prior to the delivery of such notice, except that the liquidated damages described
herein shall be payable through the date notice of revocation or rescission is given to the Company. 
  

	(e)	Legends. 

 (i) Restrictive Legend. The Holder understands
that until such time as this Warrant, the Exercise Shares and the Redemption Shares, as applicable, have been registered under the Securities Act as contemplated by the Registration Rights Agreement or otherwise may be sold pursuant to Rule 144
under the Securities Act or an exemption from registration under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold or as otherwise may be appropriate, this Warrant,
the Exercise Shares and the Redemption Shares, as applicable, shall bear any or all of the restrictive legends in substantially the following forms (and a stop-transfer order may be placed against transfer of the certificates for such securities):

 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS (I) A REGISTRATION STATEMENT REGISTERING SUCH SECURITIES UNDER THE
SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE, (II) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OR
QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS, INCLUDING PURSUANT TO A SO-CALLED “4(1) AND A HALF” SALE, OR (III) SUCH SECURITIES ARE SOLD PURSUANT TO RULE 144 OR RULE 144A.” 
 “THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN REGISTRATION
RIGHTS AGREEMENT DATED AS OF JUNE 26, 2008, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD
OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.” 
 “THE COMPANY SHALL NOT ISSUE PURSUANT TO THIS CERTIFICATE AND ANY OTHER
WARRANT CERTIFICATES OR OTHER SECURITIES OF THE COMPANY ISSUED PURSUANT TO THE FACILITY AGREEMENT DATED AS OF JUNE 26, 2008 (THE “FACILITY AGREEMENT”), AS AMENDED FROM TIME TO TIME, AND THE HOLDER SHALL HAVE NO RIGHT TO ACQUIRE
PURSUANT TO THIS CERTIFICATE AND ANY OTHER WARRANT CERTIFICATES OR OTHER SECURITIES OF THE COMPANY ISSUED PURSUANT TO THE FACILITY AGREEMENT, ANY SHARES OF COMMON STOCK UPON EXERCISE AND/OR CONVERSION OF THIS CERTIFICATE AND ANY OTHER WARRANT
CERTIFICATES OR OTHER SECURITIES OF THE COMPANY ISSUED PURSUANT TO THE FACILITY AGREEMENT, THAT WOULD IN THE AGGREGATE EXCEED 13,675,091 SHARES OF COMMON STOCK. COPIES OF THE FACILITY AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY
THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.” 
 (ii) Removal of Restrictive Legends. This Warrant, the certificates
evidencing the Exercise Shares and any Redemption Shares (as defined below), as applicable, shall not contain any legend restricting the transfer thereof (including the applicable legend set forth above in Section 2(e)(i)): (A) while a
registration statement (including a Registration Statement, as defined in the Registration Rights Agreement, or any Shelf Registration Statement with respect to Redemption Shares, as defined in 

  


					
		 	-3-	 	[  *  ] Confidential Treatment Requested









 
Section 4(c) below) covering the sale or resale of such security is effective under the Securities Act, or (B) following any sale of such Warrant,
Exercise Shares and/or Redemption Shares pursuant to Rule 144, or (C) if such Warrant, Exercise Shares and/or Redemption Shares are eligible for sale under Rule 144(b)(1)(i), or (D) if such legend is not required under applicable
requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) and the Company shall have received an opinion of counsel of Holder to such effect (collectively, the “Unrestricted
Conditions”). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date (as defined below) if required by the Company’s transfer agent to effect the issuance of the Exercise Shares
or any Redemption Shares without a restrictive legend or removal of the legend hereunder. If the Unrestricted Conditions are met at the time of issuance of this Warrant, Exercise Shares and/or Redemption Shares, then such Warrant, Exercise Shares
and/or Redemption Shares shall be issued free of all legends. The Company agrees that following the Effective Date or at such time as the Unrestricted Conditions are met or such legend is otherwise no longer required under this Section 2(e), it
will, no later than three (3) Trading Days following the delivery (the “Unlegended Shares Delivery Deadline”) by the Holder to the Company or the Transfer Agent of this Warrant and a certificate representing Exercise Shares or
Redemption Shares, as applicable, issued with a restrictive legend (such third Trading Day, the “Legend Removal Date”), deliver or cause to be delivered to such Holder this Warrant and/or a certificate (or electronic transfer) representing
such shares that is free from all restrictive and other legends. For purposes hereof, “Effective Date” shall mean the date that the Registration Statement that the Company is required to file pursuant to the Registration Rights Agreement
or any Shelf Registration Statement pursuant to Section 4(c) below has been declared effective by the SEC. 
 (iii) Sale of Unlegended Shares.
Holder agrees that the removal of the restrictive legend from this Warrant and any certificates representing securities as set forth in Section 2(e)(ii) above is predicated upon the Company’s reliance that the Holder will sell this
Warrant, Exercise Shares and/or Redemption Shares pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold
pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein. 
 (f) Cancellation of Warrant.
This Warrant shall be canceled upon the full Exercise of this Warrant or upon full redemption of this Warrant. As soon as practical after the Date of Exercise, Holder shall be entitled to receive Common Stock for the number of shares purchased upon
such Exercise of this Warrant, and if this Warrant is not Exercised in full, Holder shall be entitled to receive a new Warrant (containing terms identical to this Warrant) representing any unexercised portion of this Warrant in addition to such
Common Stock. 
 (g) Holder of Record. Each person in whose name any Warrant for shares of Common Stock is issued shall, for all purposes, be deemed
to be the Holder of record of such shares on the Date of Exercise of this Warrant, irrespective of the date of delivery of the Common Stock purchased upon the Exercise of this Warrant. Nothing in this Warrant shall be construed as conferring upon
Holder any rights as a shareholder of the Company. 
 (h) Delivery of Electronic Shares. In lieu of delivering physical certificates representing the
Common Stock issuable upon Exercise or legend removal or representing Redemption Shares, provided the Company’s Transfer Agent is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer
(“FAST”) program, upon written request of the Holder, the Company shall use reasonable efforts to cause its Transfer Agent to electronically transmit the Common Stock issuable to the Holder by crediting the account of the Holder’s
prime broker with DTC through its Deposit Withdrawal Agent Commission (DWAC) system. The time periods for delivery and penalties described herein shall apply to the electronic transmittals described herein. Any delivery not effected by electronic
transmission shall be effected by delivery of physical certificates. 
 (i) Buy-In. In addition to any other rights available to the Holder, if the
Company fails to cause its Transfer Agent to transmit to the Holder a certificate or certificates representing the Exercise Shares pursuant to an Exercise on or before the Delivery Period, and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Exercise Shares which the Holder anticipated receiving
upon such Exercise (a “Buy-In”), then the Company shall (1) pay in cash to the Holder the amount by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so
purchased exceeds (y) the amount obtained by multiplying (A) the number of Exercise Shares that the Company was required to deliver to the Holder in connection with the Exercise at issue times and (B) the price at which the sell order
giving rise to such purchase obligation was executed, and (2) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares for which such Exercise was not honored or deliver to the Holder the
number of shares of Common Stock that would have been issued had the Company timely complied with its Exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a
Buy-In with respect to an attempted Exercise to cover the sale of 

  


					
		 	-4-	 	[  *  ] Confidential Treatment Requested









 
Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (1) of the immediately preceding sentence,
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In, together with applicable confirmations and other evidence reasonably
requested by the Company. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with
respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon Exercise of the Warrant as required pursuant to the terms hereof. 
  

	3.	Payment of Warrant Exercise Price. 

 (a) Exercise. The
Exercise Price (“Exercise Price”) shall initially equal $             per share subject to adjustment pursuant to the terms hereof, including but not limited to
Section 5 below. 
 The Holder may only exercise this Warrant in a cashless exercise transaction. In order to effect a Cashless Exercise, the Holder
shall surrender this Warrant at the principal office of the Company together with notice of exercise, in which event the Company shall issue Holder a number of shares of Common Stock computed using the following formula (a “Cashless
Exercise”): 
 X = Y (A-B)/A 
 where: X =
the number of shares of Common Stock to be issued to Holder. 
 Y = the number of shares of Common Stock for which this Warrant is being
Exercised. 
 A = the Market Price of one (1) share of Common Stock (for purposes of this Section 3(ii), where “Market
Price,” as of any date, means the average Volume Weighted Average Price (as defined herein) of the Company’s Common Stock during the ten (10) consecutive Trading Day period immediately preceding the date in question. 
 B = the Exercise Price. 
 As used herein, the
“Volume Weighted Average Price” for any security as of any date means the volume weighted average sale price (based on a Trading Day from 9:30 a.m. to 4:00 p.m. (New York time))) on The NASDAQ Global Market (“NASDAQ”) as reported
by, or based upon data reported by, Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereafter designated by holders of a majority in interest of the Warrants and the Company (“Bloomberg”)
or, if NASDAQ is not the principal trading market for such security, the volume weighted average sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or,
if no volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the
bid prices of any market makers for such security that are listed in the over the counter market by the Financial Industry Regulatory Authority or in the “pink sheets” by the National Quotation Bureau, Inc. If the Volume Weighted Average
Price cannot be calculated for such security for such date in the manner provided above, the volume weighted average price shall be the fair market value as mutually determined by the Company and the Holders of a majority in interest of the Warrants
being Exercised for which the calculation of the volume weighted average price is required in order to determine the Exercise Price of such Warrants. “Trading Day” shall mean any day on which the Common Sock is traded for any period on
NASDAQ, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. 
 For purposes of Rule 144
and Section (d)(3)(ii) thereof, it is intended, understood and acknowledged that the Common Stock issuable upon Exercise shall be deemed to have been acquired at the time this Warrant was issued and moreover, it is intended, understood and
acknowledged that the holding period for the Common Stock issuable upon Exercise of this Warrant shall be deemed to have commenced on the date this Warrant was issued, as provided for under applicable law. 
 (b) Dispute Resolution. In the case of a dispute as to the determination of the closing price or the Volume Weighted Average Price of the Company’s Common
Stock or the arithmetic calculation of the Exercise Price, Market Price or any Redemption Price, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of receipt, or deemed
receipt, of the Exercise Notice or Redemption Notice, or other event giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination or calculation within two
(2) Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile (i) the disputed determination of the 

  


					
		 	-5-	 	[  *  ] Confidential Treatment Requested









 
closing price or the Volume Weighted Average Price of the Company’s Common Stock to an independent, reputable investment bank selected by the Company
and approved by the Holders of a Majority in interest of the Warrants, which approval shall not be unreasonably withheld or (ii) the disputed arithmetic calculation of the Exercise Price, Market Price or any Major Transaction Warrant Redemption
Price to the Company’s independent, outside accountant. The Company shall use reasonable efforts to cause the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the
Holder of the results no later than five (5) Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be
binding upon all parties absent demonstrable error, and the Company and the Holder shall each pay one half of the fees and costs of such investment bank or accountant. 
  


	4.	Transfer and Registration. 

 (a) Transfer Rights. Subject to
the provisions of Section 8 of this Warrant, this Warrant may be transferred on the books of the Company, in whole or in part, in person or by attorney, upon surrender of this Warrant properly completed and endorsed; provided, however, that any
transfer of this Warrant or any portion hereof shall be for a portion of the Warrant representing the right to purchase at least 100,000 shares of Common Stock (as such amount may be adjusted from time to time pursuant to Section 5(b) hereof)
unless such transfer is for the entire remaining portion of this Warrant then held by the Holder. This Warrant shall be canceled upon such surrender and, as soon as practicable thereafter, the person to whom such transfer is made shall be entitled
to receive a new Warrant or Warrants as to the portion of this Warrant transferred, and Holder shall be entitled to receive a new Warrant as to the portion hereof retained. 
 (b) Registrable Securities. The Common Stock issuable upon the Exercise of this Warrant has registration rights pursuant to the Registration Rights Agreement. 
 (c) Registration of Redemption Shares. The Company agrees to prepare and file with the SEC one or more “shelf” registration statement(s) on Form S-3 for
an offering to be made on a continuous basis pursuant to Rule 415 of the Securities Act following issuance of this Warrant, and to use reasonable best efforts to cause any such Shelf Registration Statement to become effective as soon as
possible after such filing, covering the issuance of a sufficient number of shares of Common Stock that may be delivered by it upon a redemption of this Warrant under Sections 5(c)(iii) or 11 or in satisfaction of any Failure Payments (as
defined in Section 10 below) under Section 10 (the “Shelf Registration Statement”). For so long as all or any portion of this Warrant is outstanding, the Company agrees to use its reasonable best efforts to ensure that any Shelf
Registration Statement shall continuously be effective and contain a sufficient number of shares of Common Stock available to be issued pursuant to any such Shelf Registration Statement to cover shares estimated by the Company in good faith that may
be issuable by it upon a redemption of this Warrant under Sections 5(c)(iii) or 11 or in satisfaction of any Failure Payments under Section 10, including by preparing and filing such amendments (including post-effective amendments) and
supplements to any such Shelf Registration Statement and preparing and filing a subsequent Shelf Registration Statement if a previously filed and effective Shelf Registration Statement will no longer be deemed current and effective or such Shelf
Registration Statement does not cover a sufficient number of shares that may be issuable by the Company upon a redemption of this Warrant under Sections 5(c)(iii) or 11 or in satisfaction of any Failure Payments under Section 10. To the
extent the Shelf Registration Statement provided for under this paragraph is effective, at any time that shares of Common Stock are issuable to the Holder upon a redemption of the Warrant under Sections 5(c)(iii) or 11 or in satisfaction of any
Failure Payments under Section 10, such shares delivered to the Holder shall be registered pursuant to such Shelf Registration Statement. Notwithstanding anything to the contrary herein (i) the Company may delay or suspend the
effectiveness of a Shelf Registration Statement or the use of any prospectus forming a part of a Shelf Registration Statement due to the non-disclosure of material, non-public information concerning the Company, the disclosure of which at the time
is not in its best interest of the Company in the good faith opinion of the Company; provided that no such periods shall individually exceed 45 days or in the aggregate exceed 90 days during any 12-month period and (ii) a delay in the
effectiveness of a Shelf Registration Statement caused solely by the filing of a request for confidential treatment shall not be deemed an Event of Failure or an Event of Default herein. 
 “Redemption Shares” means shares of Common Stock of the Company that may be issuable from time to time pursuant to Section 5(c)(iii), 10 and/or 11 hereof and that are registered for sale under the
Securities Act pursuant to a Shelf Registration Statement as contemplated by this Section 4(c) or, if such a registration statement is not then effective, shares of Common Stock of the Company that are not so registered. 
  

	5.	Adjustments Upon Certain Events. 

 (a) Participation. The
Holder, as the holder of this Warrant, shall be entitled to receive such dividends paid and distributions of any kind made to the holders of Common Stock of the Company to the same extent as if the Holder had 

  


					
		 	-6-	 	[  *  ] Confidential Treatment Requested









 
Exercised this Warrant into Common Stock (without regard to any limitations on exercise herein or elsewhere and without regard to whether or not a sufficient
number of shares are authorized and reserved to effect any such exercise and issuance) and had held such shares of Common Stock on the record date for such dividends and distributions. Payments under the preceding sentence shall be made concurrently
with the dividend or distribution to the holders of Common Stock. 
 (b) Recapitalization or Reclassification. If the Company shall at any time effect
a recapitalization, reclassification or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or smaller number of shares, then upon the effective date thereof, the
number of shares of Common Stock which Holder shall be entitled to purchase upon Exercise of this Warrant shall be increased or decreased, as the case may be, in direct proportion to the increase or decrease in the number of shares of Common Stock
by reason of such recapitalization, reclassification or similar transaction, and the Exercise Price shall be, in the case of an increase in the number of shares, proportionally decreased and, in the case of decrease in the number of shares,
proportionally increased. The Company shall give Holder the same notice it provides to holders of Common Stock of any transaction described in this Section 5(b). 
  

	(c)	Rights Upon Major Transaction. 

 (i) Major Transaction. In
the event that a Major Transaction (as defined below) occurs, and unless the Holder waives its rights under this Section with respect to such Major Transaction, the Holder, at its option, may require the Company to either (A) redeem the
Holder’s outstanding Warrants in accordance with Section 5(c)(iii) below or (B) if the conditions set forth in Section 5(c)(ii) below are satisfied, elect to have the Major Transaction treated as an Assumption. 
 Each of the following events shall constitute a “Major Transaction”: 
 (A) a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event, (1) following which the holders of Common Stock immediately preceding such consolidation, merger, exchange,
recapitalization, reorganization, combination or event either (a) no longer hold a majority of the shares of Common Stock or (b) no longer have the ability to elect a majority of the board of directors of the Company or (2)(x) as a
result of which shares of Common Stock shall be changed into (or the shares of Common Stock become entitled to receive) the same or a different number of shares of the same or another class or classes of stock or securities of another entity and
(y) the holders of equity interests in the Company immediately preceding such consolidation, merger, exchange, recapitalization, reorganization, combination or event do not hold a substantially equivalent percentage of equity interest of the
other entity immediately following such consolidation, merger, exchange, recapitalization, reorganization, combination or event (collectively, a “Change of Control Transaction”); 
 (B) the sale or transfer (excluding the grant of a security interest or lien or similar rights) in one transaction or in a series of related transactions (i) of all
or substantially all of the assets of the Company or (ii) of assets for a purchase price equal to more than [  *  ]; 
 (C) a
purchase, tender or exchange offer made to the holders of outstanding shares of Common Stock, such that following such purchase, tender or exchange offer a Change of Control Transaction shall have occurred and is completed; 
 (D) the liquidation, bankruptcy, insolvency, dissolution or winding-up (or the occurrence of any analogous proceeding) of the Company; or 
 (E) the shares of Common Stock cease to be listed, traded or publicly quoted on the NASDAQ Global Market and are not promptly re-listed or requoted on the New York Stock
Exchange, the American Stock Exchange, the NASDAQ Global Select Market or the NASDAQ Capital Market. 
 (ii) Assumption.
[  *  ]. Upon the occurrence of any Major Transaction treated as an Assumption hereunder, any Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Major Transaction, the
provisions of this Warrant and the Registration Rights Agreement (or substantially similar instruments, if applicable) referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the
Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of the Major Transaction, the Successor Entity shall deliver
to the Holder confirmation that there shall be issued upon exercise or redemption of this Warrant at any time after the consummation of the Major Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other
property) issuable upon the exercise of the Warrants prior to such Major Transaction, such shares of common stock (or their equivalent) of the Successor Entity (or such shares of publicly traded common stock (or their equivalent) if the Successor
Entity is a Publicly Traded Successor Entity), as adjusted in accordance with the provisions of this Warrant. The 

  


					
		 	-7-	 	[  *  ] Confidential Treatment Requested









 
provisions of this Section 5.2(c)(ii) shall apply similarly and equally to successive Major Transactions and shall be applied without regard to any
limitations on the exercise of this Warrant other than any applicable limitations. Any assumption of Company obligations under this Section 5.2(c)(ii) shall be referred to herein as an “Assumption”. 
 (iii) Notice; Major Transaction Redemption Right. At least thirty (30) days prior to the consummation of any Major Transaction, but, in any event, no later
than three (3) Business Days following the public announcement of such Major Transaction, the Company shall deliver written notice thereof via facsimile and overnight courier to the Holder (a “Major Transaction Notice”)
[  *  ]. At any time during the period beginning after the Holder’s receipt of a Major Transaction Notice and ending five (5) Trading Days prior to the scheduled consummation of such Major Transaction, the Holder
may require the Company to redeem (a “Redemption Upon Major Transaction”) all or any portion of this Warrant not to be so assumed pursuant to the provisions of Section 5(c)(ii) by delivering written notice thereof (“Major
Transaction Redemption Notice”) to the Company, which Major Transaction Redemption Notice shall indicate the portion of the principal amount (the “Redemption Principal Amount”) of the Warrant that the Holder is electing to have
redeemed. The portion of this Warrant to be redeemed pursuant to this Section 5(c)(iii) shall be redeemed by the Company at a price (the “Major Transaction Warrant Redemption Price”) payable (x) in the case of a Cash-Out Major
Transaction (as defined below) or in the case of a Mixed Major Transaction (as defined below) to the extent of the percentage of the cash consideration in such Mixed Major Transaction (determined in accordance with the definition of a Mixed Major
Transaction below), in cash equal to the “Black Scholes Value” determined by use of the Black Scholes Option Pricing Model using the criteria set forth in Schedule 1 hereto (the “Black Scholes Value”), and (y) in the case of
a Major Transaction not described in the foregoing proviso (x) or to the extent of the percentage of the consideration represented by securities of the Successor Entity in a Mixed Major Transaction (as determined in accordance with the
definition of Mixed Major Transaction below), in a number of shares of Redemption Shares equal to the Black Scholes Value of the portion of this Warrant subject to redemption under this clause (y) divided by [  *  ]%
of the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then being traded on the Trading Day immediately preceding the date on which the Major Transaction is consummated;
provided, however, that Holder shall only receive up to such amount of shares of Common Stock such that Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Holder’s
for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities
that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than 9.98% of the total number of shares of Common Stock of the Company then issued and
outstanding; and, provided further, that the foregoing proviso shall not be construed to require any cash payment by the Company of any remaining amount of any Major Transaction Warrant Redemption Price. 
 For purposes hereof, the “Black-Scholes” value of a Warrant (or a portion thereof) shall be determined by use of the Black Scholes Option Pricing Model using
the criteria set forth on Schedule 1 hereto. 
 (iv) Escrow; Payment of Major Transaction Warrant Redemption Price. Following the receipt of a Major
Transaction Redemption Notice from the Holder, the Company shall not consummate a Major Transaction that is being treated as a redemption in accordance with Section 5(c)(iii) above, unless either it obtains the written agreement of the
Successor Entity that payment of the Major Transaction Warrant Redemption Price shall be made to the Holder upon consummation of such Major Transaction or it shall first place into an escrow account with an independent escrow agent, at least three
(3) Business Days prior to the closing date of the Major Transaction (the “Major Transaction Escrow Deadline”), an amount in shares of Common Stock or cash, as applicable, equal to the Major Transaction Warrant Redemption Price.
Concurrently upon closing of such Major Transaction, the Company shall have paid or shall instruct the escrow agent to pay the Major Transaction Warrant Redemption Price to the Holder. For purposes of determining the amount required to be placed in
escrow pursuant to the provisions of this Section (5)(c)(iv) and without affecting the amount of the actual Major Transaction Warrant Redemption Price, the calculation of the price referred to in clause (1) of the first column of Schedule
1 hereto with respect to Stock Price shall be determined based on the Closing Market Price (as defined therein) of the Common Stock using the Trading Day immediately preceding the date that the funds are deposited with the escrow agent. 

(v) Injunction. Following the receipt of a Major Transaction Redemption Notice from the Holder, in the event that the Company attempts to consummate a Major
Transaction without either placing the Major Transaction Warrant Redemption Price in escrow in accordance with Section 5(c)(iv) above or obtaining the written agreement of the Successor Entity that payment of the Major Transaction Warrant
Redemption Price will be made to the Holder upon consummation of such Major Transaction, the Holder shall have the right to apply for an injunction in any state or federal courts sitting in the City of New York, borough of Manhattan to prevent the
closing of such Major Transaction until the Major Transaction Warrant Redemption Price is paid to the Holder, in full. 
  


					
		 	-8-	 	[  *  ] Confidential Treatment Requested









 Redemptions required by this Section 5(c) shall be made in accordance with the provisions of Section 12 and
shall have priority to payments to holders of Common Stock in connection with a Major Transaction. To the extent redemptions required by this Section 5(c)(iii) are deemed or determined by a court of competent jurisdiction to be prepayments of
the Warrant by the Company, such redemptions shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 5, until the Major Transaction Warrant Redemption Price is paid in full, this Warrant may be
exercised, in whole or in part, by the Holder into shares of Common Stock, or in the event the Exercise Date is after the consummation of the Major Transaction, shares of common stock (or their equivalent) of the Successor Entity pursuant to
Section 5(c). The parties hereto agree that in the event of the Company’s redemption of any portion of the Warrant under this Section 5(c), the Holder’s damages would be uncertain and difficult to estimate because of the
parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium due under this Section 5(c) is intended by the
parties to be, and shall be deemed, a reasonable estimate of the Holder’s actual loss of its investment opportunity and not as a penalty. 
 For
purposes hereof: 
 “Cash-Out Major Transaction” means a Major Transaction in which the consideration payable to holders of Common Stock in
connection with the Major Transaction consists solely of cash. 
 “Eligible Market” means the over the counter Bulletin Board, the New York Stock
Exchange, Inc., the NYSE Arca, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market or the American Stock Exchange. 
 “Mixed Major Transaction” means a Major Transaction where the consideration payable to shareholders of the Company consists partially of cash and partially of securities of a Successor Entity. If the Successor Entity is a Publicly
Traded Successor Entity, the percentage of consideration represented by securities of such Successor Entity shall be equal to the quotient of (x) the product of the aggregate anticipated number of shares of the Publicly Traded Successor Entity
to be issued (based on the Trading Day preceding the first public announcement of the Mixed Major Transaction) to holders of Common Stock of the Company multiplied by the closing market price for such shares of the Publicly Traded Successor Entity
on its principal securities exchange on the Trading Day preceding the first public announcement of the Mixed Major Transaction, divided by (y) the sum of the amount determined in subclause (x) plus the aggregate value of other
consideration, including cash consideration, in such Major Transaction. If the Successor Entity is a Private Successor Entity, the percentage of consideration represented by securities of such Successor Entity shall be determined in good-faith by
the Company’s Board of Directors. 
 “Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person,
or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest fair market value as of the date of consummation of a Major Transaction (as determined in good-faith by the Company’s Board of Directors).

 “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated
organization, any other entity and a government or any department or agency thereof. 
 “Private Successor Entity” means a Successor Entity that is
not a Publicly Traded Successor Entity. 
 “Publicly Traded Successor Entity” means a Successor Entity that is a publicly traded corporation whose
common stock is quoted on or listed for trading on an Eligible Market (as defined above). 
 (d) Exercise Price Adjusted. As used in this Warrant, the
term “Exercise Price” shall mean the purchase price per share specified in Section 3(a) of this Warrant, until the occurrence of an event stated in this Section 5 or otherwise set forth in this Warrant, and thereafter shall mean
said price as adjusted from time to time in accordance with the provisions of said subsection. No adjustment made pursuant to any provision of this Section 5 shall have the net effect of increasing or decreasing the Exercise Price in relation
to the split adjusted and distribution adjusted price of the Common Stock. 
 (e) Adjustments: Additional Shares, Securities or Assets. In the event
that at any time, as a result of an adjustment made pursuant to this Section 5 or otherwise, Holder shall, upon Exercise of this Warrant, become entitled to receive shares and/or other securities or assets (other than Common Stock) then,
wherever appropriate, all references herein to shares of Common Stock shall be deemed to refer to and include such shares and/or other securities or assets; and thereafter the number of such shares and/or other securities or assets shall be subject
to adjustment from time to time in a manner and upon terms as nearly equivalent as practicable to the provisions of this Section 5. 
  


					
		 	-9-	 	[  *  ] Confidential Treatment Requested









 (f) Notice of Adjustments. Whenever the Exercise Price is adjusted pursuant to the terms of this Warrant, the
Company shall promptly mail to the Holder a notice (an “Exercise Price Adjustment Notice”) setting forth the Exercise Price after such adjustment and setting forth a statement of the facts requiring such adjustment. The Company shall, upon
the written request at any time of the Holder, furnish to such Holder a like Warrant setting forth (i) such adjustment or readjustment, (ii) the Exercise Price at the time in effect and (iii) the number of shares of Common Stock and
the amount, if any, of other securities or property which at the time would be received upon Exercise of the Warrant. For purposes of clarification, whether or not the Company provides an Exercise Price Adjustment Notice pursuant to this
Section 5(f), upon the occurrence of any event that leads to an adjustment of the Exercise Price, the Holders would be entitled to receive a number of Exercise Shares based upon the new Exercise Price, as adjusted, for exercises occurring on or
after the date of such adjustment, regardless of whether a Holder accurately refers to the adjusted Exercise Price in the Exercise Form. 
  

	6.	Fractional Interests. 

 No fractional shares or scrip representing
fractional shares shall be issuable upon the Exercise of this Warrant, but on Exercise of this Warrant, Holder may purchase only a whole number of shares of Common Stock. If, on Exercise of this Warrant, Holder would be entitled to a fractional
share of Common Stock or a right to acquire a fractional share of Common Stock, such fractional share shall be disregarded and the number of shares of Common Stock issuable upon Exercise shall be the next higher number of shares. 
  

	7.	Reservation of Shares. 

 From and after the date hereof, the
Company shall at all times reserve for issuance such number of authorized and unissued shares of Common Stock (or other securities substituted therefor as herein above provided) as shall be sufficient for the Exercise of this Warrant and payment of
the Exercise Price as estimated by the Company in good faith. If at any time the number of shares of Common Stock authorized and reserved for issuance is below the number of shares sufficient for the Exercise of this Warrant (a “Share
Authorization Failure”) (based on the Exercise Price in effect from time to time) as estimated by the Company in good faith, the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares,
including, without limitation, calling a special meeting of shareholders to authorize additional shares to meet the Company’s obligations under this Section 7, in the case of an insufficient number of authorized shares, and using
reasonable best efforts to obtain shareholder approval of an increase in such authorized number of shares. The Company covenants and agrees that upon the Exercise of this Warrant, all shares of Common Stock issuable upon such Exercise shall be duly
and validly issued, fully paid and nonassessable and not subject to preemptive rights, rights of first refusal or similar rights of any person or entity. 
  

	8.	Restrictions on Transfer. 

 (a) Registration or Exemption
Required. This Warrant has been issued in a transaction exempt from the registration requirements of the Securities Act by virtue of Regulation D and exempt from state registration under applicable state laws. The Warrant, the Common Stock
issuable upon the Exercise of this Warrant and any Redemption Shares issued pursuant hereto may not be pledged, transferred, sold or assigned except pursuant to an effective registration statement, pursuant to Rule 144 or after receipt by the
Company of an opinion of counsel for the Holder that any such pledge, transfer, sale or assignment shall be exempt from the registration requirements of the Securities Act and applicable state laws, including, without limitation, a so-called
“4(1) and a half” transaction. The Holder agrees to comply with the reporting obligations applicable to it under Section 16 of the Exchange Act with respect to this Warrant, the Warrant Shares, the Redemption Shares and any other
shares of Common Stock beneficially owned by it. 
 (b) Assignment. Subject to Section 8(a), the Holder may sell, transfer, assign, pledge or
otherwise dispose of this Warrant, in whole or in part; provided, however, that any sale, transfer, assignment, pledge or other disposition of this Warrant of any portion hereof shall relate to a portion of the Warrant representing the right to
purchase at least 100,000 shares of Common Stock (as such amount may be adjusted from time to time pursuant to Section 5(b) hereof) unless such disposition relates to the entire remaining outstanding portion of this Warrant then held by such
Holder. Holder shall deliver a written notice to Company, substantially in the form of the Assignment attached hereto as Exhibit B, indicating the person or persons to whom the Warrant shall be assigned and the respective number of Warrant Shares to
be assigned to each assignee. The Company shall effect the assignment within three (3) Business Days of its receipt of a properly completed and executed form of Assignment and, if required by this Warrant, receipt by the Company of an opinion
of counsel (the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a Warrant or Warrants of like tenor and terms for the appropriate number of shares. This Warrant and the rights evidenced hereby shall
inure to the benefit of and be binding upon the successors and assigns of the Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder.
For avoidance of doubt, in the event Holder 

  


					
		 	-10-	 	[  *  ] Confidential Treatment Requested









 
notifies the Company that such sale or transfer is a so called “4(1) and half” transaction, the parties hereto agree that a legal opinion from
outside counsel for the Holder delivered to counsel for the Company substantially in the form attached hereto as Exhibit C shall be the only opinion requirement to satisfy an exemption from registration under the Securities Act to effectuate such
“4(1) and half” transaction. 
  

	9.	Noncircumvention. 

 The Company hereby covenants and agrees that
the Company will not, by amendment of its articles of incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be reasonably required to protect the rights of the
Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, and (ii) shall
take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant. 
  

	10.	Events of Failure; Definition of Black Scholes Value. 

  

	(a)	Definitions. 

 The occurrence of each of the following shall be
considered to be an “Event of Failure.” 
 (i) A Delivery Failure occurs, where a “Delivery Failure” shall be deemed to
have occurred if the Company fails to use reasonable best efforts to deliver Exercise Shares to the Holder within any applicable Delivery Period (other than due to the limitations set forth in Section 1); 
 (ii) A Legend Removal Failure occurs, where a “Legend Removal Failure” shall be deemed to have occurred if the Company fails to use reasonable
best efforts to issue this Warrant and/or Exercise Shares without a restrictive legend, or fails to use reasonable best efforts to remove a restrictive legend, when and as required under Section 2(e) hereof; 
 (iii) a Transfer Delivery Failure occurs, where a “Transfer Delivery Failure” shall be deemed to have occurred if the Company fails to use
reasonable best efforts to deliver a Warrant within any applicable Transfer Delivery Period; and 
 (iv) a Registration Failure (as defined
below) (subject to any Grace Periods). 
 For purpose hereof, “Registration Failure” means that (A) the Company fails to file with the SEC on
or before the Filing Deadline (as defined in the Registration Rights Agreement) any Registration Statement required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, or (B) the Company fails to use reasonable best
efforts to obtain effectiveness with the SEC, prior to the Registration Deadline (as defined in the Registration Rights Agreement), and if such Registration Statement is not so filed prior to the Registration Deadline, as soon as possible
thereafter, of any Registration Statement (as defined in the Registration Rights Agreement) required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, or fails to use reasonable best efforts to keep such Registration
Statement current and effective as required in Section 3 of the Registration Rights Agreement, (C) the Company fails to file any amendment to the Registration Statement, or any additional Registration Statement required to be filed
pursuant to Section 3(b) of the Registration Rights Agreement within thirty (30) days of the applicable Registration Trigger Date (as defined in the Registration Rights Agreement), or fails to use reasonable best efforts to cause such
amendment and/or new Registration Statement to become effective within sixty (60) days of the applicable Registration Trigger Date, and, if such effectiveness does not occur within such period, as soon as possible thereafter, or (iv) any
Registration Statement required to be filed under the Registration Rights Agreement, after its initial effectiveness and during the Registration Period (as defined in the Registration Rights Agreement), lapses in effect or sales of all of the
Registrable Securities (as defined in the Registration Rights Agreement) cannot otherwise be made thereunder (whether by reason of the Company’s failure to amend or supplement the prospectus included therein in accordance with the Registration
Rights Agreement, the Company’s failure to file and use reasonable best efforts to obtain effectiveness with the SEC of an additional Registration Statement or amended Registration Statement required pursuant to Section 3 of the
Registration Rights Agreement or otherwise, but subject to Section 3(q) of the Registration Rights Agreement), (D) the Company fails to provide a reasonable written response to any comments to any Registration Statement submitted by the
SEC within twenty-five (25) days of the date that such SEC comments are received by the Company or (E) the Company fails to file with the SEC the Shelf Registration Statement(s) as required under 

  


					
		 	-11-	 	[  *  ] Confidential Treatment Requested









 
Section 4(c) hereof and to use reasonable best efforts to cause any such Registration Statement(s) to become effective as soon as possible after such
filing and to use reasonable best efforts to ensure that any such Shelf Registration Statement shall continuously be effective, in each case, in accordance with Section 4(c) hereof, in each case other than as a result of the failure of any
Holder or Buyer (as defined in the Registration Rights Agreement) to provide applicable information or otherwise comply with its obligations under the Registration Rights Agreement). 
 (b) Failure Payments; Black-Scholes Determination. The Company understands that any Event of Failure (as defined above) could result in economic loss to the Holder. In the event that any Event of Failure occurs
(other than an Event of Failure caused by the submission of any incomplete or inaccurate information required to be furnished by the Holder, as compensation to the Holder for such loss, the Company agrees to pay (as liquidated damages and not as a
penalty) to the Holder an amount payable in Redemption Shares that are valued for these purposes at [ * ]% of the Volume Weighted Average Price on the date of such calculation (“Failure Payments”) at a rate of 18% per
annum (or the maximum rate permitted by applicable law, whichever is less) of the Black-Scholes value (as determined below) of the remaining unexercised portion of this Warrant on the date of such Event of Failure (as recalculated on the first
Business Day of each month thereafter for as long as Failure Payments shall continue to accrue), which shall accrue daily from the date of such Event of Failure until the Event of Failure is cured, accruing daily and compounded monthly, provided,
however, the Holder shall receive up to such amount of Redemption Shares such that Holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of
the Exchange Act (including shares held by any “group” of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to
convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than 9.98% of the total number of shares of Common Stock of the Company then issued and outstanding; and, provided further,
that the foregoing proviso shall not be construed to require any cash payment by the Company of any remaining amount of any Failure Payment. For purposes of clarification, it is agreed and understood that Failure Payments shall continue to accrue
following any Event of Default until the applicable Default Amount is paid in full. 
 Notwithstanding the above, in the event that the Company (i) has,
by the Filing Deadline (as defined the Registration Rights Agreement) filed a Registration Statement (as defined in the Registration Rights Agreement) covering the number of shares required by the Registration Rights Agreement, (ii) has
responded in writing to any comments to the Registration Statement that the Company has received from the SEC, within ten (10) Business Days of such receipt, and nevertheless the SEC has not declared effective a Registration Statement covering
the full number of Warrant Shares issuable upon exercise of the Warrants by the Registration Deadline (as defined in the Registration Rights Agreement) and (iii) any Failure Payments are required, then the Failure Payments attributable to such
late Registration Effectiveness shall be reduced from 18% to 15% (calculated as set forth above). The Company shall satisfy any Failure Payments incurred under this Section pursuant to Section 10(c) below. Failure Payments are in addition to
any Shares that the Holder is entitled to receive upon Exercise of this Warrant. 
 For purposes hereof, the “Black-Scholes” value of a Warrant
shall be determined by use of the Black-Scholes Option Pricing Model using the criteria set forth on Schedule 1 hereto. 
 (c) Payment of Accrued Failure
Payments. The shares representing accrued Failure Payments for each Event of Failure shall be issued and delivered on or before the tenth (10th) Business Day of each month following a month in which Failure Payments accrued. Nothing herein
shall limit the Holder’s right to pursue actual damages (to the extent in excess of the Failure Payments) for the Company’s Event of Failure, and the Holder shall have the right to pursue all remedies available at law or in equity
(including a decree of specific performance and/or injunctive relief). Notwithstanding the above, if a particular Event of Failure results in an Event of Default pursuant to Section 11 hereof, then the Failure Payment, for that Event of Failure
only, shall be considered to have been satisfied upon payment to the Holder of an amount equal to the greater of (i) the Failure Payment, or (ii) the Default Amount payable in accordance with Section 11. 
 (d) Maximum Interest Rate. Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be deemed to establish or
require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum permitted by such
law, any payments in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company. 
  

	11.	Default and Redemption. 

 (a) Events Of Default. Each of the
following events shall be considered to be an “Event of Default,” unless waived by the Holder: 
  


					
		 	-12-	 	[  *  ] Confidential Treatment Requested









 (i) Failure To Effect Registration. With respect to all Registration Failures other than as provided in
clause (E) of the definition of “Registration Failure”, a Registration Failure occurs and remains uncured for a period of more than thirty (30) (or ninety (90) days in the case where the Company (i) has, by the Filing
Deadline (as defined the Registration Rights Agreement) filed a Registration Statement (as defined in the Registration Rights Agreement) covering this Warrant and the number of shares required by the Registration Rights Agreement, and (ii) has
responded in writing to any comments to the Registration Statement that the Company has received from the SEC, within ten (10) Business Days of such receipt, and nevertheless the SEC has not declared effective a Registration Statement covering
this Warrant and the Shares by the Registration Deadline (as defined in the Registration Rights Agreement)) and such Registration Failure relates solely to the Company’s failure to have the Registration Statement declared effective by the
Registration Deadline (as defined in the Registration Rights Agreement); and with respect to a Registration Failure provided in clause (E) of the definition of “Registration Failure”, such Registration Failure occurs and remains
uncured for a period of more than thirty (30) days. 
 (ii) Failure To Deliver Common Stock. A Delivery Failure (as defined above) occurs and
remains uncured for a period of more than [ * ] ([ * ]) days; or at any time, the Company announces or states in writing that it will not honor its obligations to issue shares of Common Stock to the Holder upon
Exercise by the Holder of the Exercise rights of the Holder in accordance with the terms of this Warrant. 
 (iii) Legend Removal Failure. A Legend
Removal Failure (as defined above) occurs and remains uncured for a period of thirty (30) days; and 
 (iv) Corporate Existence; Major
Transaction. The Company has consummated a Major Transaction without paying the Major Transaction Warrant Redemption Price, as required, to the Holder pursuant to Section 5(c)(iii) or, if the Holder elected an Assumption pursuant to
Section 5(c)(ii), the Company has failed to meet the Assumption requirements of Section 5(c)(ii) prior to consummating a Major Transaction, as required. 
  

	(b)	Mandatory Redemption. 

 (i) Mandatory Redemption Amount. If
any Events of Default shall occur then, unless waived by the Holder, upon the occurrence and during the continuation of any Event of Default, at the option of the Holder, such option exercisable through the delivery of written notice to the Company
by such Holder (the “Default Notice”), the outstanding amount of this Warrant shall be immediately redeemed by the Company and the Company shall pay to the Holder (a “Mandatory Redemption”), in full satisfaction of its
obligations hereunder, an amount in Redemption Shares that are valued for these purposes at [ * ]% of the average Volume Weighted Average Price for the five (5) Business Days prior to the date of the applicable Default Notice
(the “Mandatory Redemption Amount” or the “Default Amount”) equal to the greater of (i) the Black-Scholes value (as determined in accordance with Section 10(b)) of the remaining unexercised portion of this Warrant on
the date of such Default Notice and (2) the Black-Scholes value (also as determined in accordance with Section 10(b)) of the remaining unexercised portion of this Warrant on the Trading Day immediately preceding the date that the Mandatory
Redemption Amount is paid to the Holder, provided, however, Holder shall receive up to such amount of Redemption Shares such that Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be
aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of
securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than 9.98% of the total number of shares of
Common Stock of the Company then issued and outstanding; and, provided further, that the foregoing proviso shall not be construed to require any cash payment by the Company of any remaining amount of any Mandatory Redemption Amount. 
 The shares representing the Mandatory Redemption Amount shall be issued within seven (7) Business Days following the date of the applicable Default Notice, if
provided pursuant to the terms of this Warrant. 
 (ii) Liquidated Damages. The parties hereto acknowledge and agree that the sums payable as Failure
Payments or pursuant to a Mandatory Redemption shall give rise to liquidated damages and not penalties. The parties further acknowledge that (i) the amount of loss or damages likely to be incurred by the Holder is incapable or is difficult to
precisely estimate, (ii) the amounts specified bear a reasonable proportion and are not plainly or grossly disproportionate to the probable loss likely to be incurred by the Holder, and (iii) the parties are sophisticated business parties
and have been represented by sophisticated and able legal and financial counsel and negotiated this Agreement at arm’s length. 
 (c) Remedies, Other
Obligations, Breaches And Injunctive Relief. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, the Facility Agreement and the Registration Rights Agreement, at law or in
equity (including a decree of specific performance and/or other injunctive relief), and nothing 

  


					
		 	-13-	 	[  *  ] Confidential Treatment Requested









 
herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or
threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being
required. 
  

	Section	12. Holder’s Redemptions. 

 In the event that the Holder has
sent a Default Notice or a Major Transaction Redemption Notice to the Company pursuant to Section 5(c) or a Default Notice pursuant to Section 11(b)(i), respectively (each, a “Redemption Notice”), the Holder shall promptly submit
this Warrant to the Company. If the Holder has submitted a Major Transaction Redemption Notice in accordance with Section 5(c)(iii), the Company shall deliver the applicable Major Transaction Warrant Redemption Price to the Holder concurrently
with or prior to the consummation of such Major Transaction pursuant to the payment terms of such transaction. In the event that the Company does not pay the applicable Major Transaction Warrant Redemption Price to the Holder within the time period
required, at any time thereafter and until the Company pays such unpaid Major Transaction Warrant Redemption Price in full, the Holder shall have the option, in lieu of redemption, to require the Company to promptly return to the Holder all or any
portion of this Warrant that was submitted for redemption and for which the applicable Major Transaction Warrant Redemption Price (together with any late charges thereon) has not been paid. Upon the Company’s receipt of such notice,
(x) the applicable Redemption Notice shall be null and void with respect to such Redemption Principal Amount, (y) the Company shall immediately return this Warrant, or issue a new Warrant to the Holder representing the portion of this
Warrant that was submitted for redemption and (z) the Exercise Price of this Warrant or such new Warrant shall be adjusted to the lesser of (A) the Exercise Price as in effect on the date on which the applicable Redemption Notice is voided
and (B) the lowest closing price for the Common Stock on NASDAQ, or, if NASDAQ is not the principal trading market for the Common Stock, the principal securities exchange or other securities market on which the Common Stock is then being
traded, during the period beginning on and including the date on which the applicable Redemption Notice is delivered to the Company and ending on and including the date on which the applicable Redemption Notice is voided. The Holder’s delivery
of a notice voiding a Redemption Notice and exercise of its rights following such notice shall not affect the Company’s obligations to make any payments of Failure Payments which have accrued prior to the date of such notice with respect to the
Warrant subject to such notice. 
  

	13.	Benefits of this Warrant. 

 Nothing in this Warrant shall be
construed to confer upon any person other than the Company and Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and Holder. 
  

	14.	Governing Law. 

 All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees
that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees
or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any
claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The
parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for
its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. 
  


					
		 	-14-	 	[  *  ] Confidential Treatment Requested










	15.	Loss of Warrant. 

 Upon receipt by the Company of evidence of the
loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of indemnity or security reasonably satisfactory to the Company, and upon surrender and cancellation of this Warrant, if mutilated, the Company
shall execute and deliver a new Warrant of like tenor and date. 
  

	16.	Notice or Demands. 

 Notices or demands pursuant to this Warrant to
be given or made by Holder to or on the Company shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service or by certified or registered mail, return receipt requested, postage prepaid,
and addressed, until another address is designated in writing by the Company, to the address set forth in Section 2(a) above. Notices or demands pursuant to this Warrant to be given or made by the Company to or on Holder shall be sufficiently
given or made if sent by overnight delivery with a nationally recognized overnight courier service or by certified or registered mail, return receipt requested, postage prepaid, and addressed, to the address of Holder set forth in the Company’s
records, until another address is designated in writing by Holder. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  


					
		 	-15-	 	[  *  ] Confidential Treatment Requested









 IN WITNESS WHEREOF, the undersigned has executed this Warrant as of the _____ day of _______________, ____. 

 

			
	ZYMOGENETICS, INC.
		
	By:	 	 
		 	 Print Name:
 Title:



  


					
		 	-16-	 	[  *  ] Confidential Treatment Requested









 EXHIBIT A 
 EXERCISE FORM FOR WARRANT 
 TO: ZYMOGENETICS, INC. 
 The undersigned hereby irrevocably Exercises the right to purchase
                     of the shares of Common Stock (the “Common Stock”) of ZYMOGENETICS, INC., a Washington corporation (the
“Company”), evidenced by the attached warrant (the “Warrant”), and herewith makes payment of the Exercise Price with respect to such shares in full, all in accordance with the conditions and provisions of said Warrant.

 1.     The undersigned agrees not to offer, sell, transfer or otherwise dispose of any of the Common Stock obtained on Exercise of the
Warrant, except in accordance with the provisions of Section 8 of the Warrant. 
 2.     The undersigned requests that any stock
certificates for such shares be issued free of any restrictive legend, if appropriate, and a warrant representing any unexercised portion hereof be issued, pursuant to the Warrant in the name of the undersigned and delivered to the undersigned at
the address set forth below. 
 3.     The undersigned is exercising the attached Warrant pursuant to Cashless Exercise as set forth in
the Warrant. 
 Dated:                                      
                       
  
  
  
 Signature 
  
  
  
 Print Name 
  
  
  
 Address 
 NOTICE 
 The signature to the foregoing Exercise Form must correspond to the name as written upon the face of the attached Warrant in every particular, without alteration or
enlargement or any change whatsoever. 
  


					
		 	A-1	 	[  *  ] Confidential Treatment Requested









 EXHIBIT B 
 ASSIGNMENT 
 (To be executed by the registered holder 
 desiring to transfer the Warrant) 
 FOR VALUE RECEIVED, the undersigned holder of the attached warrant
(the “Warrant”) hereby sells, assigns and transfers unto the person or persons below named the right to purchase
                     shares of the Common Stock of ZYMOGENETICS, INC., a Washington corporation, evidenced by the attached Warrant and
does hereby irrevocably constitute and appoint                      attorney to transfer the said Warrant on the books of the Company, with
full power of substitution in the premises. 
 The undersigned hereby certifies that the Warrant is being sold, assigned or transferred in accordance with
Section 8 of the Warrant and all applicable securities laws. 
  

					
	Dated:                                      
                      	 		 	
			
	 	 		 	  
		 		 	Signature

 Fill in for new registration of Warrant: 
  

					
			
	  	 		 	 
	Name	 		 	
			
	  	 		 	 
	Address	 		 	
			
	  	 		 	 
	 Please print name and address of assignee
 (including zip
code number)
	 		 	

 NOTICE 
 The
signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Warrant in every particular, without alteration or enlargement or any change whatsoever. 
  


					
		 	B-1	 	[  *  ] Confidential Treatment Requested









 EXHIBIT C 
 FORM OF OPINION 
                     , 20     
 [                    ] 
  

	Re:	Zymogenetics, Inc. (the “Company”) 

 Dear Sir:

 [                    ]
(“[                    ]”) intends to transfer
                     Warrants (the “Warrants”) of the Company to
                    
(“                    ”) without registration under the Securities Act of 1933, as amended (the “Securities Act”). In
connection therewith, we have examined and relied upon the truth of representations contained in an Investor Representation Letter attached hereto and have examined such other documents and issues of law as we have deemed relevant. 
 Based on and subject to the foregoing, we are of the opinion that the transfer of the Warrants by
                     to
                     may be effected without registration under the Securities Act, provided, however, that the Warrants to be transferred to
                     contain a legend restricting its transferability pursuant to the Securities Act and that transfer of the Warrants is
subject to a stop order. 
 The foregoing opinion is furnished only to
                             and may not be used, circulated, quoted or otherwise referred to or
relied upon by you for any purposes other than the purpose for which furnished or by any other person for any purpose, without our prior written consent. 
 Very truly yours, 
  


					
		 	C-1	 	[  *  ] Confidential Treatment Requested









 [FORM OF INVESTOR REPRESENTATION LETTER] 
                     , 20         
 [                    ] 
 Gentlemen: 
                      (“            ”) has agreed to
purchase                      Warrants (the “Warrants”) of Zymogenetics, Inc. (the “Company”) from
[            ] (“[            ]”). We understand that the Warrants are “restricted securities.”
We represent and warrant that ______ is a sophisticated institutional investor that qualifies as an “Accredited Investor” as defined in Rule 501 of Regulation D under the Securities Act of 1933, as amended (the “Securities
Act”). 
 ________ represents and warrants as of the date hereof as follows: 
 1. That it is acquiring the Warrants and the shares of common stock, no par value per share, underlying such Warrants (the “Exercise
Shares”) solely for its account for investment and not with a view to or for sale or distribution of said Warrants or Exercise Shares or any part thereof. ________ also represents that the entire legal and beneficial interests of the Warrants
and Exercise Shares _________ is acquiring is being acquired for, and will be held for, its account only; 
 2. That the
Warrants and the Exercise Shares have not been registered under the Securities Act on the basis that no distribution or public offering of the stock of the Company is to be effected. _______ realizes that the basis for the exemption may not be
present if, notwithstanding its representations, _______ has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in,
or otherwise distributing the securities. _______ has no such present intention; 
 3. That the Warrants and the Exercise
Shares must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. ________ recognizes that the Company has no obligation to register the Warrants, or to comply with
any exemption from such registration; 
 4. That neither the Warrants nor the Exercise Shares may be sold pursuant to
Rule 144 adopted under the Securities Act unless certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about Company, the resale
following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations; 
 5. That it will not make any disposition of all or any part of the Warrants or Exercise Shares in any event unless and until: 

(i) There is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition
is made in accordance with said registration statement; or 
 (ii) _________ shall have notified the Company of the proposed
disposition and, in the case of a sale or transfer in a so-called “4(1) and a half” transaction, shall have furnished counsel to the Company with an opinion of counsel, reasonably satisfactory to counsel to the Company, that no
registration under the Securities Act or qualification under any state securities laws is required for the proposed disposition. 
 We acknowledge that if a
registration statement is not effective, the Warrant and the Exercise Shares shall bear in substantially similar form any or all of the following restrictive legends: 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD,
TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS (I) A REGISTRATION STATEMENT REGISTERING SUCH SECURITIES UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS 

  


					
		 		 	[  *  ] Confidential Treatment Requested









 
SHALL HAVE BECOME EFFECTIVE, OR (II) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT
REGISTRATION UNDER THE SECURITIES ACT OR QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS INCLUDING PURSUANT TO A SO-CALLED “4(1) AND A HALF” TRANSACTION, OR (III) SUCH SECURITIES ARE SOLD PURSUANT TO RULE 144 OR
RULE 144A.” 
 “THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND
CONDITIONS OF A CERTAIN REGISTRATION RIGHTS AGREEMENT DATED AS OF JUNE 26, 2008, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN
REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.” 
 “THE COMPANY SHALL NOT ISSUE PURSUANT
TO THIS CERTIFICATE AND ANY OTHER WARRANT CERTIFICATES OR OTHER SECURITIES OF THE COMPANY ISSUED PURSUANT TO THE FACILITY AGREEMENT DATED AS OF JUNE 26, 2008 (THE “FACILITY AGREEMENT”), AS AMENDED FROM TIME TO TIME, AND THE HOLDER
SHALL HAVE NO RIGHT TO ACQUIRE PURSUANT TO THIS CERTIFICATE AND ANY OTHER WARRANT CERTIFICATES OR OTHER SECURITIES OF THE COMPANY ISSUED PURSUANT TO THE FACILITY AGREEMENT, ANY SHARES OF COMMON STOCK UPON EXERCISE AND/OR CONVERSION OF THIS
CERTIFICATE AND ANY OTHER WARRANT CERTIFICATES OR OTHER SECURITIES OF THE COMPANY ISSUED PURSUANT TO THE FACILITY AGREEMENT, THAT WOULD IN THE AGGREGATE EXCEED 13,675,091 SHARES OF COMMON STOCK. COPIES OF THE FACILITY AGREEMENT MAY BE OBTAINED AT NO
COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.” 
 At any time and from time to time after
the date hereof, _________ shall, without further consideration, execute and deliver to [            ] or the Company such other instruments or documents and shall take such other
actions as they may reasonably request to carry out the transactions contemplated hereby. 
 Very truly yours, 
  


					
		 	-2-	 	[  *  ] Confidential Treatment Requested









 Schedule 1 
 Black-Scholes Value 
  

							
	 	  	 Calculation Under Section 5(c)(iii)
	  	  	  	 Calculation Under Section 10(b) or 11(b)

				
	Remaining Term    	  	Number of calendar days from date of public announcement of the Major Transaction until the last date on which the Warrant may be exercised.	  		  	Number of calendar days from date of the Event of Failure until the last date on which the Warrant may be exercised.
				
	Interest Rate	  	A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the Remaining Term.	  		  	A risk-free interest rate corresponding to the US$ LIBOR/ Swap rate for a period equal to the Remaining Term.
				
	Volatility	  	[ * ]	  		  	[ * ]
				
	Stock Price	  	[ * ]	  		  	[ * ]
				
	Dividends	  	Zero.	  		  	Zero.

  


					
		 	S-1	 	[  *  ] Confidential Treatment Requested